Back to CVE records
High 8.7Published Jun 11, 2026

CVE-2026-53901Cerebrate before version 1.37 contains a mass-assignment vulnerability in the generic CRUD add path.

Updated under an hour ago ()

Does this affect you?

It lists no affected products yet. Add what you run and Signals checks it as products are added.

No exploitation reported and no EPSS estimate yet.

Cerebrate before version 1.37 contains a mass-assignment vulnerability in the generic CRUD add path. The add() handler attempted to remove an attacker-supplied id from $params before normalizing the request through __massageInput(). Because the normalized $input could still contain an id field, a user able to reach an affected add endpoint could supply an identifier that should have been server-controlled. Successful exploitation could allow creation of objects with attacker-chosen identifiers, potentially causing unauthorized data manipulation, object spoofing, inconsistent references, or disruption through identifier collisions, depending on the affected model and endpoint permissions. The issue was fixed in v1.37 by removing id from the normalized input before entity patching.

CVSS
8.7 HIGH (v4.0, NVD)CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:Amber
Weakness (CWE)
CWE-20
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Deferred
Record last updated
Jul 23, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

No affected products are listed yet.

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.